undamentalytics Newsletter
Sign in

Surrozen, Inc. revenue

Surrozen, Inc.'s revenue was $3.5m in fiscal 2025, down 67.4% on the year before. Since fiscal 2022 ($12.5m) it has grown at a compound -34.7% a year. Over the last twelve months it was $11.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue013011312
Growth on the year before——−100.0%—−67.4%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Research Service Revenue $3.5M 100.0% ▲ 430.8%
Collaboration and License Revenue $0 0.0% ▼ 100.0%

From Surrozen, Inc.'s 10-K filed March 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Surrozen, Inc. $11.5m -8.8% —
Mindwalk Holdings Corp. $11.3m 47.8% —
Relay Therapeutics, Inc. $10.3m 23.9% 122.3%
Lineage Cell Therapeutics, Inc. $13.1m 19.9% 7.5%
Caribou Biosciences, Inc. $10.0m 10.0% -11.0%
Opus Genetics, Inc. $9.9m -36.1% -39.8%

Compare with peers

Head to head: HYFT vs SRZNRLAY vs SRZNLCTX vs SRZN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Surrozen, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Surrozen, Inc.